Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $12
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $13 to $12.
Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $13 to $12.
